132945-76-7

Basic information

• Product Name: (R)-1-Boc-3-cyanopyrrolidine
• Synonyms: (R)-1-Boc-3-cyanopyrrolidine;(R)-1-Boc-3-cyanopyrrolid...;tert-butyl (3R)-3-cyanopyrrolidine-1-carboxylate;(R)-N-Boc-Cyanopyrrolidine;(R)-1-N-Boc-3-Cyano-pyrrolidine(R)-1-N-Boc-3-Cyano-pyrrolidine
• CAS NO: 132945-76-7
• Molecular Formula: C₁₀H₁₆N₂O₂
• Molecular Weight: 196.25
• Product Categories: Pyrrole&Pyrrolidine&Pyrroline
• Mol File: 132945-76-7.mol

Chemical Properties

• Boiling Point: 307.9 °C at 760 mmHg
• Flash Point: 140 °C
• Appearance: /
• Density: 1.08 g/cm³
• Vapor Pressure: 0.000703mmHg at 25°C
• Refractive Index: 1.488
• Storage Temp.: 2-8°C
• PKA: -3.73±0.40(Predicted)
• BRN: 8683216
• CAS DataBase Reference: (R)-1-Boc-3-cyanopyrrolidine(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-1-Boc-3-cyanopyrrolidine(132945-76-7)
• EPA Substance Registry System: (R)-1-Boc-3-cyanopyrrolidine(132945-76-7)

Safety Data

• Hazard Codes: Xn
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• Hazardous Substances Data: 132945-76-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
(R)-1-Boc-3-cyanopyrrolidine is used as a key intermediate in the synthesis of β-proline analogs, such as (3R)-carboxy pyrrolidine. These analogs are valuable in the development of novel drugs with improved pharmacological properties and selectivity.
Used in Antimicrobial Agents:
(R)-1-Boc-3-cyanopyrrolidine is used in the preparation of 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic Acid compounds, which exhibit anti-microbial properties. These compounds can be employed as potential therapeutic agents against various microbial infections, contributing to the development of new antibiotics and antimicrobial drugs.

InChI:InChI=1/C10H16N2O2/c1-10(2,3)14-9(13)12-5-4-8(6-11)7-12/h8H,4-5,7H2,1-3H3/t8-/m0/s1

Upstream product

• 2408-36-8 lithium cyanide 
• 132945-75-6 (S)-tert-butyl 3-(methylsulfonyloxy)pyrrolidine-1-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 101469-92-5 (S)-3-hydroxy-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 143-33-9 sodium cyanide 
• 773837-37-9 sodium cyanide 

Downstream Products

• 471254-10-1 (3R)-pyrrolidine-3-carboxamide 
• 199174-29-3 tert-butyl (R)-3-(aminomethyl)pyrrolidine-1-carboxylate 
• 199175-10-5 1,1-dimethylethyl (3S)-3-(aminomethyl)-1-pyrrolidinecarboxylate 
• 1366767-72-7 1,1-dimethylethyl (3R)-3-{[5-(4-bromophenyl)-1H-tetrazol-1-yl]methyl}-1-pyrrolidinecarboxylate 
• 1366767-74-9 5-(4-bromophenyl)-1-{[(3R)-1-(cyclopropylcarbonyl)-3-pyrrolidinyl]methyl}-1H-tetrazole 

Relevant articles and documents

FATTY ACID SYNTHASE INHIBITORS

This invention relates to carboxamides and reverse carboxamides according to Formula (I) and the use of carboxamides and reverse carboxamides for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of carboxamides and reverse carboxamides in the treatment of cancer.

FATTY ACID SYNTHASE INHIBITORS

This invention relates to the use of imidazole, triazole, and tetrazole derivatives for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of imidazoles, triazoles, and tetrazoles in the treatment of cancer.

BENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS

This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of benzimidazoles in the treatment of cancer.

AZABENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS

This invention relates to the use of azabenzimidazole derivatives for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of azabenzimidazoles in the treatment of cancer.

FUSED HETEROCYCLIC COMPOUND

The present invention relates to a fused heterocyclic compound having the Formula 1, which is useful as a platelet aggregation inhibitor, a method for preparing the same, and a pharmaceutical composition for inhibiting platelet aggregation comprising the same.

QUINAZOLINE DERIVATIVES

The invention concerns quinazoline derivatives of Formula (I) wherein each of R1, R3, R20, X1, X2, Z, W, (a) and (q) have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of turnours which are sensitive to inhibition of erbB receptor tyrosine kinases, particularly EGFR tyrosine kinase.

ANTITHROMBOTIC AGENTS

Compounds of formula (I): Are antithrombotic agents, having utility in a variety of therapeutic areas including the prevention and/or treatment of deep vein thrombosis (DVT) after surgery, major medical illness, paralysis, malignancy, prolonged immobilisa

Synthesis of (3R)-carboxy pyrrolidine (a β-proline analogue) and its oligomer

A decamer of a β-amino acid analogue of L-proline, (3R)-carboxy pyrrolidine (β-proline), was synthesized from a readily available (R)-glycidol. It was found to possess a rigid secondary structure, as evidenced by its CD spectrum. The β-proline decamer, however, failed to bind to profilin, whereas the corresponding α-L-proline decamer bound tightly to this protein. (C) 2000 Published by Elsevier Science Ltd.

Antithrombotic agents

Compounds of formula (I) : are antithrombotic agents, having utility in a variety of therapeutic areas including the prevention and/or treatment of deep vein thrombosis (DVT) after surgery, major medical illness, paralysis, malignancy, prolonged immobilis

1-methylcarbapenem derivatives

A 1-methylcarbapenem compound represented by the following formula: STR1 [wherein R1 represents a hydrogen atom or a lower alkyl group, R2 represents a hydrogen atom or a lower alkyl group, R3 represents a hydrogen atom, a